TruScreen2 Sales to China commence following CFDA Approval

NZX and Media Release 21 December, 2017
NZX Limited
WELLINGTON

TruScreen2 Sales to China commence following CFDA Approval

Cervical cancer screening technology company, TruScreen Limited (NZAX: TRU) advises that,
following on from receipt of China Food and Drug Administration (CFDA) approval for its new
TruScreen2 device, as announced on 4 December 2017, it has now received an initial payment of
NZ$188,000 against initial orders from its Chinese distributor.
TruScreen chair, Robert Hunter, said “The establishment of a market for TruScreen2 in China has
been a major focus for the company and, as previously announced, there has been strong interest in
TruScreen2 pending CFDA approval. The company is now producing consoles at its maximum
capacity to meet current and anticipated orders from China which is our largest target market.”

ENDS
For more information visit www.truscreen.com or contact:
Martin Dillon
TruScreen Chief Executive Officer
Email: martindillon@truscreen.com
Media Liaison
Jackie Ellis
Email: jackie@ellisandco.co.nz
Phone: +64 27 246 2505

About TruScreen:
TruScreen’s real time cervical cancer technology
utilises a digital wand which is placed on the
surface of the cervix to measure electrical and
optical signals from the surrounding tissue. A
sophisticated proprietary algorithm framework
distinguishes between normal and abnormal
(cancerous and precancerous) tissue to identify
precancerous change, or cervical intraepithelial
neoplasia (CIN). A Single Use Sensor (SUS) is used
for each patient to protect against cross-infection.